Vinblastine chemotherapy in adult patients with langerhans cell histiocytosis: a multicenter retrospective study

Table 5 Univariate analyses of risk factors for neurotoxicity^a

Characteristic	No neurologic toxicity (=25)	Neurologic toxicity (n = 9)	p-value
Age, years, median, [IQR]	31.6 [28–39.6]	33.6 [25.7–48.7]	0.74
Male sex, n (%)	17 (71%)	5 (56%)	0.44
Smoker, n (%)	12 (52%)	6 (67%)	0.28
Ex-smoker	5 (22%)	3 (33%)
Non-smoker	6 (26%)	0
LCH stratification
MS	20 (80%)	7 (78%)	1.00
SS	5 (21%)	2 (22%)
Previous risk factor of neuropathy^a	5 (20%)	3 (33%)	0.65
Vinblastine Treatment
Number of injections, median, [IQR]	17 [13.5; 21]	29 [21; 49]	0.085
Cumulative dose, mg, median, [IQR]	152.8 [120; 210]	168 [130; 220]	0.38
Duration of exposure, months, median, [IQR]	7.6 [5.4; 12.0]	7.6 [6.2; 9.9]	0.90

IQR interquartile range, LCH Langerhans cell histiocytosis, MS multisystem, SS single system
^aData on risk factors were available for 34 patients

ISSN: 1750-1172